Stay updated with breaking news from Sight Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study demonstrates contralateral transfer of LUMEVOQ after unilateral injection Results suggest mechanistic explanation for bilateral improvement of visual function among ND4-LHON patients
December 2, 2021, at 8:00 am EST 2:00 pm CET Connection details for live call and translation provided Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US - read this article along with other careers information, tips and advice on BioSpace
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update ATUs in France in Europe in H1 2022 Successful refinancing in Q1 2021 secures mid-2023 runway Multiple regulatory and clinical milestones expected in Q4 2021 Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 20...